Dergiler / Turkish Journal of Biology / 2017 / Cilt: 41 - Sayı: 1

Th1 cells in cancer-associated inflammation

Sayfa
20–30
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here, the current insights on Th1 cells during cancer-associated inflammatory responses are reviewed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The immune system is not only evolved to protect the body from pathogens, but it also recognizes and eliminates cancer cells.
📊
Temel Bulgular & Veri:CD4+ helper T (Th) lymphocytes are central intercessors differentiated according to the character of physiological or pathological status.
💡
Sonuç & Katkı:Here, the current insights on Th1 cells during cancer-associated inflammatory responses are reviewed.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

The immune system is not only evolved to protect the body from pathogens, but it also recognizes and eliminates cancer cells. CD4+ helper T (Th) lymphocytes are central intercessors differentiated according to the character of physiological or pathological status. Generation of type 1 Th (Th1) cells is primarily associated with a pathological insult that must be removed through immune elimination. Upon interacting with other immune and transformed cells, Th1 cells can hamper cancer progression. Therefore, it is a major obstacle for tumor cells to become insensitive or resistant to Th1-oriented actions. The organism employs various mechanisms to return to a steady state and ensure tissue repair following a destructive inflammatory response. Th1 cells are also tightly regulated during the termination of immune responses. They can reduce the production of inflammatory cytokines, both generate and be prone to inhibitory signals, and undergo activation-induced cell death for inflammation resolution. Additionally, Th1 cells may become hyporesponsive, exhausted, and decorated with many inhibitory receptors and eventually lose functionality. There is growing evidence about tumor cells taking advantage of the strategies used for the resolution of Th1-oriented inflammation. Here, the current insights on Th1 cells during cancer-associated inflammatory responses are reviewed.

🔖

Bu Makaleye Atıf Yap

DİNÇ, G. A., ESENDAĞLI, G., ÖZKAZANÇ, D. (2022). Th1 cells in cancer-associated inflammation. Turkish Journal of Biology, Cilt: 41 - Sayı: 1, 20–30. https://ajindex.com/articles/654404

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Abbas AK, Lichtman AH, Pillai S (2014). Cellular and Molecular Immunology. 8th ed. Philadelphia, PA, USA: Elsevier Saunders. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M (2015). IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112: 1501-1509.
  2. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998). Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
  3. Bos R, Sherman LA (2010). CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70: 8368-8377.
  4. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C (2013). T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361-365.
  5. Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, Kammertoens T (2011). Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 128: 371-378.
  6. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM (2011). Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 18: 23-34.
  7. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA (2014). Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 44: 69-79.
  8. Corazza N, Brumatti G, Schaer C, Cima I, Wasem C, Brunner T (2004). TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ 11 (Suppl. 2): S122-125. Cousins DJ, Lee TH, Staynov DZ (2002). Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol 169: 2498-506.
  9. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF (1999). Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162: 3256-3262.
  10. De Groot RP, Coffer PJ, Koenderman L (1998). Regulation of proliferation, differentiation and survival by the IL-3/IL-5/ GM-CSF receptor family. Cell Signal 10: 619-628.
  11. Delves PJ, Roitt IM (2011). Roitt’s Essential Immunology. 12th ed. Chichester, UK: Wiley-Blackwell. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J et al. (1994). Abnormal development of peripheral lymphoid org